Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q2 2022 · 10-Q
Revenue$91.00K$91.00K+33.8% vs Q2 2021 Net Income-$10.44M-$10.44MN/M vs Q2 2021 EPS Diluted-$0.24-$0.24N/M vs Q2 2021 Operating Income-$10,443,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$7,007,000N/M Margins · derivedOperating margin-11475.8%−1344.9 pt vs Q2 2021
Net margin-11475.8%−1539.1 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 4, 2022 · 35 d after period end